PT2760479T - Métodos de monitorização da terapêutica com fármacos eliminadores de azoto - Google Patents

Métodos de monitorização da terapêutica com fármacos eliminadores de azoto

Info

Publication number
PT2760479T
PT2760479T PT128354073T PT12835407T PT2760479T PT 2760479 T PT2760479 T PT 2760479T PT 128354073 T PT128354073 T PT 128354073T PT 12835407 T PT12835407 T PT 12835407T PT 2760479 T PT2760479 T PT 2760479T
Authority
PT
Portugal
Prior art keywords
narcotic
methods
therapeutics
monitoring
eliminating drugs
Prior art date
Application number
PT128354073T
Other languages
English (en)
Portuguese (pt)
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2760479(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of PT2760479T publication Critical patent/PT2760479T/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • G01N31/221Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4925Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • Y10T436/173845Amine and quaternary ammonium
    • Y10T436/175383Ammonia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Ecology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
PT128354073T 2011-09-30 2012-03-09 Métodos de monitorização da terapêutica com fármacos eliminadores de azoto PT2760479T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161542100P 2011-09-30 2011-09-30
US201161564668P 2011-11-29 2011-11-29

Publications (1)

Publication Number Publication Date
PT2760479T true PT2760479T (pt) 2017-07-21

Family

ID=47892277

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128354073T PT2760479T (pt) 2011-09-30 2012-03-09 Métodos de monitorização da terapêutica com fármacos eliminadores de azoto

Country Status (25)

Country Link
US (21) US8404215B1 (enExample)
EP (2) EP2760479B1 (enExample)
JP (2) JP6073898B2 (enExample)
KR (2) KR102019000B1 (enExample)
CN (2) CN104039358A (enExample)
AU (2) AU2012316750B2 (enExample)
BR (1) BR112014007357B1 (enExample)
CA (1) CA2850391A1 (enExample)
CL (1) CL2014000783A1 (enExample)
CY (1) CY1119028T1 (enExample)
DK (1) DK2760479T3 (enExample)
ES (1) ES2629859T3 (enExample)
HR (1) HRP20171063T1 (enExample)
HU (1) HUE035220T2 (enExample)
IL (2) IL231732A (enExample)
LT (1) LT2760479T (enExample)
MX (2) MX366197B (enExample)
PL (1) PL2760479T3 (enExample)
PT (1) PT2760479T (enExample)
RS (1) RS56196B1 (enExample)
SG (1) SG11201400781TA (enExample)
SI (1) SI2760479T1 (enExample)
SM (1) SMT201700321T1 (enExample)
WO (1) WO2013048558A2 (enExample)
ZA (1) ZA201401851B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2760479T3 (pl) 2011-09-30 2017-09-29 Horizon Therapeutics, Llc Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
CN111991383A (zh) * 2012-04-20 2020-11-27 伊梅尔迪卡制药公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) * 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
US20150094278A1 (en) * 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
PT2986325T (pt) * 2013-10-14 2019-10-09 Immedica Pharma Ab Métodos para tratar distúrbios do ciclo da ureia
EP3782610A1 (en) 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof
ES2861594T3 (es) 2014-04-30 2021-10-06 Univ Johns Hopkins Composiciones de dendrímeros y su uso en el tratamiento de enfermedades del ojo
WO2015187641A1 (en) * 2014-06-04 2015-12-10 Horizon Therapeutics, Inc. Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
AU2015301575B2 (en) 2014-08-13 2018-05-10 The Johns Hopkins University Selective dendrimer delivery to brain tumors
JP7088473B2 (ja) 2015-10-29 2022-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
WO2017147193A1 (en) * 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JP6752748B2 (ja) 2017-03-30 2020-09-09 住友重機械工業株式会社 減速装置
JP7454945B2 (ja) * 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
MX2020002057A (es) * 2017-08-22 2020-07-13 Regeneron Pharma Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス, インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
WO2022011061A1 (en) * 2020-07-07 2022-01-13 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004595A (en) 1911-05-25 1911-10-03 Sargents Sons Corp C G Carrier for washing-bowls.
US1018300A (en) 1911-06-12 1912-02-20 John Davidson Condensing steam-engine.
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) * 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
IT1317073B1 (it) 2000-12-12 2003-05-26 Mini Ricerca Scient Tecnolog Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US6825384B1 (en) 2004-01-29 2004-11-30 The Nutrasweet Company Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
ES2593378T3 (es) 2008-08-29 2016-12-09 Horizon Therapeutics, Llc Métodos de tratamiento usando fármacos de secuestro de ammonia
WO2010025303A1 (en) 2008-08-29 2010-03-04 Hyperion Therapeutics Dosing and monitoring patients on nitrogen-scavenging drugs
EP2456304B1 (en) 2009-07-24 2015-08-19 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
EP2594550B1 (en) 2010-07-16 2016-10-12 Tohoku University Method for oxidizing alcohols
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
PL2760479T3 (pl) 2011-09-30 2017-09-29 Horizon Therapeutics, Llc Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
CN111991383A (zh) 2012-04-20 2020-11-27 伊梅尔迪卡制药公司 苯乙酸前药的治疗性监测方法
LT2922576T (lt) 2012-11-21 2018-02-12 Horizon Therapeutics, Llc Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai
CN103304402B (zh) 2013-05-24 2015-04-22 苏州诚和医药化学有限公司 一种制备4-苯-1-丁酸的方法
US20150094278A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy
PT2986325T (pt) 2013-10-14 2019-10-09 Immedica Pharma Ab Métodos para tratar distúrbios do ciclo da ureia
WO2015063659A1 (en) 2013-10-30 2015-05-07 Lupin Limited Process for the preparation of glycerol phenylbutyrate
WO2015187641A1 (en) 2014-06-04 2015-12-10 Horizon Therapeutics, Inc. Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
WO2017147193A1 (en) 2016-02-22 2017-08-31 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Also Published As

Publication number Publication date
US20210000784A1 (en) 2021-01-07
MX2014003854A (es) 2014-10-17
US9326966B2 (en) 2016-05-03
ZA201401851B (en) 2018-05-30
US9962358B2 (en) 2018-05-08
US10617665B2 (en) 2020-04-14
US9095559B2 (en) 2015-08-04
US10045959B1 (en) 2018-08-14
RS56196B1 (sr) 2017-11-30
US20160199334A1 (en) 2016-07-14
JP6073898B2 (ja) 2017-02-01
EP2760479B1 (en) 2017-05-03
US9999608B2 (en) 2018-06-19
JP2014532179A (ja) 2014-12-04
KR20140094517A (ko) 2014-07-30
US20180055807A1 (en) 2018-03-01
US20180263949A1 (en) 2018-09-20
BR112014007357B1 (pt) 2022-12-06
SG11201400781TA (en) 2014-04-28
SMT201700321T1 (it) 2017-09-07
US20160081969A1 (en) 2016-03-24
US20130210914A1 (en) 2013-08-15
AU2012316750B2 (en) 2017-08-31
US20180021291A1 (en) 2018-01-25
EP3263102A1 (en) 2018-01-03
JP2017067791A (ja) 2017-04-06
US20130085179A1 (en) 2013-04-04
HRP20171063T1 (hr) 2017-10-06
US10183006B2 (en) 2019-01-22
CN107271696A (zh) 2017-10-20
DK2760479T3 (en) 2017-07-17
US9962359B2 (en) 2018-05-08
IL231732A0 (en) 2014-05-28
ES2629859T3 (es) 2017-08-16
BR112014007357A2 (pt) 2017-04-04
MX2019006900A (es) 2019-09-04
US10183004B2 (en) 2019-01-22
KR102019000B1 (ko) 2019-09-05
WO2013048558A2 (en) 2013-04-04
IL254134A0 (en) 2017-10-31
CL2014000783A1 (es) 2015-01-16
CA2850391A1 (en) 2013-04-04
LT2760479T (lt) 2017-07-10
AU2017251691A1 (en) 2017-11-09
US20160199333A1 (en) 2016-07-14
US10183005B2 (en) 2019-01-22
US20190125713A1 (en) 2019-05-02
MX366197B (es) 2019-06-25
US20160202240A1 (en) 2016-07-14
US20180221325A1 (en) 2018-08-09
US20150335605A1 (en) 2015-11-26
US20180235920A1 (en) 2018-08-23
SI2760479T1 (sl) 2017-07-31
US20180021293A1 (en) 2018-01-25
KR20180085823A (ko) 2018-07-27
JP6425746B2 (ja) 2018-11-21
US20180015064A1 (en) 2018-01-18
US8404215B1 (en) 2013-03-26
WO2013048558A3 (en) 2014-04-03
US20180221324A1 (en) 2018-08-09
US10045958B1 (en) 2018-08-14
US20160199332A1 (en) 2016-07-14
IL231732A (en) 2017-09-28
EP2760479A4 (en) 2015-08-26
PL2760479T3 (pl) 2017-09-29
AU2012316750A1 (en) 2014-03-27
CN104039358A (zh) 2014-09-10
US9254278B2 (en) 2016-02-09
US20180221326A1 (en) 2018-08-09
US20180263948A1 (en) 2018-09-20
CY1119028T1 (el) 2018-01-10
EP2760479A2 (en) 2014-08-06
US10183002B2 (en) 2019-01-22
US20180221327A1 (en) 2018-08-09
US10183003B2 (en) 2019-01-22
HUE035220T2 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
PT2760479T (pt) Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
EP2699293A4 (en) SELF-INJECTOR APPARATUS
BR112013020613A2 (pt) autoinjetor
LT2775868T (lt) Rūkymo gaminys su matomu turiniu
BR112014007261A2 (pt) dispositivo de recolha de encomendas farmacêuticas
CO6920296A2 (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CO6870035A2 (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
EP2680775A4 (en) Cryogenic medical system
CO6880066A2 (es) Composición farmacéutica de sabor enmascarado
ME02958B (me) Intranazalni farmaceutski dozni oblici коji obuhvataju nalokson
EP2720699A4 (en) ADMINISTRATION OF BENZODIAZEPINE
DK3384944T3 (da) Autoinjektor
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EP2721016A4 (en) TRPV4 Antagonist
IL229963A0 (en) Substituted quinolines and their use as medicaments
SMT201500233B (it) Metodi per rilevare anticorpi anti-farmaco
BR112014013850A2 (pt) conjunto de prateleiras
FI20116007L (fi) Serotoniinitason nostaminen ja diagnostisointi
PT2736340T (pt) Biocontrolo de nemátodos
HRP20150187T1 (xx) Makrocikliäśki spojevi i postupci za njihovu proizvodnju
EP2699467A4 (en) SEGMENTED RAIL AND RAIL SEGMENT THEREFOR
SMT201400192B (it) Medicamento inalabile comprendente tiotropio
BR112014015885A8 (pt) preparação farmacêutica
CO6960557A2 (es) Derivados de 2-yodo-imidazol
EP2760629A4 (en) CONSTRUCTION OF A CONICAL STRUCTURE